Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of leukemia/lymphoma, whose diagnosis can be difficult to achieve due to its clinical and biological heterogeneity, as well as its overlapping features with other hematologic malignancies. In this study we investigated whether the association between the maturational stage of tumor cells and the clinico-biological and prognostic features of the disease, based on the analysis of 46 BPDCN cases classified into three maturation-associated subgroups on immunophenotypic grounds. Our results show that blasts from cases with an immature plasmacytoid dendritic cell (pDC) phenotype exhibit an uncommon CD56- phenotype, coexisting with CD34+ non-pDC tumor cells, typically in the absence of extramedullary (e.g. skin) disease at presentation. Conversely, patients with a more mature blast cell phenotype more frequently displayed skin/extramedullary involvement and spread into secondary lymphoid tissues. Despite the dismal outcome, acute lymphoblastic leukemia-type therapy (with central nervous system prophylaxis) and/or allogeneic stem cell transplantation appeared to be the only effective therapies. Overall, our findings indicate that the maturational profile of pDC blasts in BPDCN is highly heterogeneous and translates into a wide clinical spectrum -from acute leukemia to mature lymphoma-like behavior-, which may also lead to variable diagnosis and treatment.

Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Hodgkin's lymphoma represents one of the most frequent lymphoproliferative syndromes, especially in young population. Although HL is considered one of the most curable tumors, a sizeable fraction of patients recur after successful upfront treatment or, less commonly, are primarily resistant. This work tries to summarize the data on clinical, histological, pathological, and biological factors in HL, with special emphasis on the improvement of prognosis and their impact on therapeutical strategies. The recent advances in our understanding of HL biology and immunology show that infiltrated immune cells and cytokines in the tumoral microenvironment may play different functions that seem tightly related with clinical outcomes. Strategies aimed at interfering with the crosstalk between tumoral Reed-Sternberg cells and their cellular partners have been taken into account in the development of new immunotherapies that target different cell components of HL microenvironment. This new knowledge will probably translate into a change in the antineoplastic treatments in HL in the next future and hopefully will increase the curability rates of this disease.

Lupus nephritis: an overview of recent findings

Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE) since it is the major predictor of poor prognosis. In susceptible individuals suffering of SLE, in situ formation and deposit of immune complexes (ICs) from apoptotic bodies occur in the kidneys as a result of an amplified epitope immunological response. IC glomerular deposits generate release of proinflammatory cytokines and cell adhesion molecules causing inflammation. This leads to monocytes and polymorphonuclear cells chemotaxis. Subsequent release of proteases generates endothelial injury and mesangial proliferation. Presence of ICs promotes adaptive immune response and causes dendritic cells to release type I interferon. This induces maturation and activation of infiltrating T cells, and amplification of Th2, Th1 and Th17 lymphocytes. Each of them, amplify B cells and activates macrophages to release more proinflammatory molecules, generating effector cells that cannot be modulated promoting kidney epithelial proliferation and fibrosis. Herein immunopathological findings of LN are reviewed.

Determinación de interleucina-10 (IL-10) en pacientes con cáncer en estadios III y IV tratados con dexametasona

La utilización de la dexametasona está asociada con la supresión de la respuesta inmune en pacientes con cáncer en estadíos III y IV, debido posiblemente a una acción inhibidora sobre las células dendríticas presentadoras de antígenos. Bajo la acción de la dexametasona, las células dendríticas secretan niveles muy bajos de IL-10, lo que a su vez disminuye, tanto la respuesta mediada por los linfocitos Th2 como la inducida por las células NK. La IL-10 tiene pues un efecto dual, si se tiene en cuenta que, en la mayoría de los modelos experimentales, aumenta en pacientes tratados con glucocorticoides tipo dexametasona e inhibe la respuesta mediada por los linfocitos Th1, con una consecuente exacerbación del proceso. Metodología: Se utilizó la prueba de ELISA para determinar IL-10 en pacientes con diferentes tipos de tumor en estadíos III y IV, sometidos a quimioterapia y tratados con dexametasona-metoclopramida como antiemético y en un grupo control de personas sanas. Resultados: En este modelo experimental, todos los pacientes con cáncer en estadíos III y IV presentaron niveles séricos de IL-10 muy bajos, comparados con los del grupo control. Además, IL-10 no aumentó su concentración en los pacientes tratados con dexametasona. Conclusión: IL-10 no provoca anergia de las células dendríticas ni disminución de la respuesta citotóxica mediada por Th1. Por tanto, se sospecha que es la dexametasona y no la IL-10 la responsable de la supresión en la respuesta inmune en pacientes con cáncer en estadíos III y IV, lo que podrá ser demostrado en posteriores estudios que complementen los resultados obtenidos.

Expressão imuno-hitoquímica das proteínas RANK, RANKL e OPG em cistos radiculares e cistos dentígeros

Receptor ativador nuclear κappa B (RANK), ligante do receptor ativador nuclear κappa B (RANKL) e osteoprotegerina (OPG) são membros da família do fator de necrose tumoral relacionados com o metabolismo ósseo. A formação, diferenciação e atividade dos osteoclastos são reguladas por estas três proteínas. RANK é um receptor transmembrana presente em diversos tipos celulares, principalmente em células de linhagem macrofágica, linfócitos, células dendríticas e fibroblastos e quando ativado pelo seu ligante, RANKL, promove a diferenciação e ativação de células osteoclásticas responsáveis pelo processo de reabsorção óssea. A OPG impede a ligação RANK/RANKL atuando como um receptor inibitório para a atividade osteolítica. O objetivo deste estudo foi comparar a expressão imuno-histoquímica destes biomarcadores em cistos radiculares (n=20) e cistos dentígeros (n=20). A expressão imuno-histoquímica destes marcadores foi avaliada no epitélio e na cápsula dos cistos por escores e percentuais médios de imunomarcação. Para o epitélio, a análise semi-quantitativa revelou um padrão similar dos escores de imunomarcação de RANK, RANKL e OPG nas lesões, não havendo diferença estatística significante (p=0.589, p=0.688, p=0.709, respectivamente). Para a cápsula cística a análise quantitativa, mostrou diferença estatística significante entre os percentuais médios de imunomarcação do RANK e RANKL (p=0,001 e p=0,005, respectivamente) nos cistos. A correlação dos escores de imunomarcação de RANKL e OPG no epitélio do CR e do CD revelou diferença estatística significante (p=0,029, p=0,003, respectivamente). No epitélio dos CRs e dos CDs observou-se uma maior imunoexpressão da OPG comparada a do RANKL. Os resultados apontam a presença de RANK, RANKL e OPG nos cistos radiculares e cistos dentígeros, sugerindo a atuação destas proteínas no desenvolvimento e expansão das lesões no osso adjacente

S-100 dendritic cells in normal and Dermatobia hominis infested cattle skin

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Avaliação da resistência em caprinos a ninfas do carrapato Amblyomma cajennense (Fabricius, 1787) e da reatividade cruzada com A. hebraeum (Koch, 1844) (Acari:Ixodidae)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Estudo da atividade anti-tumoral de abrina em tumor mamário murino e sua influência no sistema imune

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Imunoterapia com a vacina heteróloga de DNA-HSP65+proteína-HSP65 de Mycobacterium leprae em tumores mamários de cadelas

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeito imunomodulador de baixas concentrações de antineoplásicos

Pós-graduação em Patologia - FMB

Perfil imunofenotípico e nível de citocinas plásmáticas em portadores de hepatite C crônica com diferentes graus de comprometimento hepático

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Técnicas e perspectivas de tratamentos imunoterápicos em câncer

Não disponível

Efeito das baixas concentrações de agentes antineoplásicos sobre linfócitos humanos de sangue periférico

Our previous studies have shown that low concentrations (noncytotoxics) of antineoplastic agents modulate positively the dendritic cells, favoring their in vitro maturation and improving their antigen presenting function. The effects on colorectal cancer cells (HCT-116) were also investigated and we have observed an increased immunogenicity and susceptibility to cytotoxic T cells. Thereby, this study aimed to investigate the effect of 5-fluorouracil (5-FU) an azacitidine (AZA), in minimum effective and noncytotoxic concentrations on lymphocytes of healthy donors. In this study we have analyzed the cytotoxic effect of drugs at these concentrations as well as the proliferative ability of lymphocytes. In vitro production of IL-10 and IFN-γ has been also evaluated. We have observed that low concentrations of those chemotherapeutic agents are not cytotoxic for lymphocytes. However, the minimum effective concentrations (5-FU: 0,410±0,088 e AZA: 0,757±0,233; p<0, 05) have reduced the cell number. Proliferative activity of allogeneic lymphocytes in a mixed reaction (MLR) was not affected by the treatment. The cytokine production was not affected by the treatments, either. In conclusion, low concentrations of 5-FU and AZA has no deleterious effects on human peripheral blood lymphocytes and seems to be safe for combinatory administration with DC vaccines

Efeito prolilático da associaçao de MOG com vitamina D na encefalomielite autoimune experimental

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Terapia gênica com interferon-alfa no controle do câncer colorretal

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)